Jazz forecasts $4.60B-$4.75B 2026 revenue as it prepares for Aug. 25 zanidatamab PDUFA (NASDAQ:JAZZ)
· seekingalpha.com
Jazz Pharmaceuticals (JAZZ) Q2 2026 earnings call: record $1.21B revenue, raised 2026 guidance, Xywav/Epidiolex trends & zanidatamab PDUFA.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...